FGL (Fibroblast Growth Loop) is a small peptide derived from the neural cell adhesion molecule (NCAM), a glycoprotein found on the surface of neurons and glial cells. By stimulating the formation of new neuronal projections and synaptic connections, FGL enhances synaptic plasticity, supports memory encoding, and provides neuroprotective benefits relevant to cognitive decline and neurodegenerative conditions.

What is FGL?

FGL (Fibroblast Growth Loop) is a peptide fragment derived from NCAM, the neural cell adhesion molecule. NCAM is a glycoprotein expressed on the surfaces of neurons and glial cells, where it plays a fundamental role in cellular adhesion, neuronal migration, and synaptic development. FGL represents a specific binding loop within the NCAM structure that, when isolated, retains the ability to stimulate neuronal growth and synapse formation. It was developed as a targeted agent for augmenting the neural plasticity and connective architecture of the brain, with particular attention to applications in cognitive decline and memory disorders.

How does FGL work?

When FGL activates NCAM-related signaling pathways, it stimulates the production of new projections from developing neurons, the structural basis for forming new synaptic connections. Because synapse formation is the cellular mechanism underlying learning and memory, FGL’s ability to promote synaptogenesis translates to improved information encoding and retrieval. Combined with enhanced synaptic transmission, this supports improved learning and memory function. FGL also provides neuronal cell protection and preservation, an additional mechanism relevant to conditions where neuronal loss drives cognitive decline, including Alzheimer’s disease.

Clinically observed benefits of FGL

• Improves cognitive function: By supporting synaptic plasticity and neuronal development, FGL has demonstrated pro-cognitive effects in research settings.
• Neuroprotective benefits: FGL supports neuronal cell preservation, protecting against the cellular loss associated with neurodegenerative conditions.
• Helps in the treatment of Alzheimer’s disease: Its synaptogenic and neuroprotective mechanisms make FGL a candidate for addressing the synaptic dysfunction central to Alzheimer’s pathology.
• Improves long and short-term memory: Enhanced synapse formation and synaptic transmission support both the encoding of new memories and the retrieval of established ones.
• Helps manage anxiety and depression: FGL’s effects on synaptic plasticity extend to mood-regulating circuits, with research supporting benefits for anxiety and depression.
• Enhances creative thinking and social interaction: Improved neural connectivity and cognitive flexibility support higher-order functions including creativity and social cognition.
• Improves brain focus and learning: By strengthening the neural architecture underlying attention and information processing, FGL supports sustained focus and accelerated learning.

How is FGL administered?

FGL is available in the following compounding format:

• Nasal spray: intranasal delivery for direct CNS uptake, bypassing the blood-brain barrier through olfactory pathways

Frequently asked questions about FGL

Q: How does FGL’s mechanism differ from other cognitive peptides like Dihexa or Semax?

A: FGL works specifically through NCAM-related pathways to stimulate neuronal projections and synaptogenesis, the physical formation of new synaptic connections. Dihexa works through HGF/c-Met receptor potentiation, while Semax primarily modulates BDNF and neuroprotective pathways. Each targets a different aspect of neural function.

Q: Why is FGL delivered as a nasal spray?

A: Intranasal delivery provides a practical route for peptides targeting the central nervous system. The olfactory pathway offers direct access to brain regions without requiring the peptide to cross the blood-brain barrier systemically, which can be a limiting factor for larger molecules.

Q: Is FGL used only for Alzheimer’s disease?

A: No. While Alzheimer’s disease is a primary research focus due to its involvement of synaptic and neuronal degeneration, FGL’s benefits for memory, learning, anxiety, depression, and general cognitive function make it relevant to a broader range of neurological and cognitive health applications.

Clinical research

Research published in PLOS Biology (Knafo et al., 2012) demonstrated that facilitation of AMPA receptor synaptic delivery is a molecular mechanism for cognitive enhancement, providing mechanistic context for FGL’s synaptogenic approach. Work by Asua et al. in Neuroscience (2018) reviewed peptides acting as cognitive enhancers, positioning FGL within the broader landscape of neurological peptide research. Wainwright and Galea’s work in Neural Plasticity (2013) on neural plasticity theory of depression and the roles of neurogenesis and PSA-NCAM further supports FGL’s potential in mood and cognitive applications.